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Previously, we have characterized the HIV-ISF2 gp120 glycopeptides using matrix-assisted
laser desorption/ionization mass spectrometry (MALDI/MS) and nanospray electrospray
ionization (ESI). Although we characterized 25 of 26 consensus glycosylation sites, we could
not obtain any information about the extent of sialylation of the complex glycans. Sialylation
is known to alter the biological activity of some glycoproteins, e.g., infectivity of some human
and nonhuman primate lentiviruses is reduced when the envelope glycoproteins are exten-
sively sialylated, and thus, characterization of the extent of sialylation of complex glycopro-
teins is of biological interest. Since neither MALDI/MS nor nanospray ESI provided much
information about sialylation, probably because of suppression effects inherent in these
techniques, we utilized online nanocapillary high performance liquid chromatography
(nHPLC) with ESI/MS to characterize the sites and extent of sialylation on gp120. Eight of the
known 26 consensus glycosylation sites of HIV-ISF2 gp120 were determined to be sialylated.
Two of these sites were previously uncharacterized complex glycans. Thirteen high mannose
sites were also determined. The heterogeneity of four of these sites had not been previously
characterized. In addition, a peptide containing two consensus glycosylation sites, which had
previously been determined to contain complex glycans, was also determined to be high
mannose as well. (J Am Soc Mass Spectrom 2004, 15, 1545–1555) © 2004 American Society for
Mass SpectrometryHuman immunodeficiency virus (HIV) is the hu-man retrovirus that causes acquired immunedeficiency syndrome (AIDS). Retroviruses are
enveloped, positive-stranded RNA viruses in which the
viral envelope is embedded with glycoproteins, known to
be involved in the early steps of infection. In HIV, the
initially formed envelope glycoprotein, gp160, is cleaved
into gp41 and gp120. gp41 is the transmembrane portion
of the glycoprotein spike and promotes cell–cell fusion
during infection. The gp120 of HIV binds to the CD4
surface molecule expressed on T-helper cells and on cells
of the macrophage lineage. Chemokine receptors are
needed as coreceptors for attachment of the HIV virus.
The gp120 structure contains five loops with varying
amino acid composition. One of these, the V3 loop, elicits
neutralizing anti-HIV antibodies and has been a target for
HIV vaccine development [1]. It has been shown that
carbohydrates within and around the V3 loop shield
binding sites for the chemokine receptors, and loss of
these carbohydrates increases infectivity [2–4]. The N-
linked glycans on this loop have been reported to strongly
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doi:10.1016/j.jasms.2004.07.008influence coreceptor usage, with CCR5 being used during
the early stages of disease and CXCR4 being used as the
disease progresses [3, 4]. The V1 and V2 variable loops
have been shown to undergo conformational changes
upon CD4 binding [5]. The V1/V2 loopsmay need to alter
their native conformation in order for the CCR5 corecep-
tor to bind with a high-affinity interaction. Also, reports
show that carbohydrates on Asp197, in the V1/V2 stem,
restrict this movement, thereby allowing the carbohy-
drates to mask the binding region [6].
HIV gp120 is highly glycosylated with a large num-
ber of consensus glycosylation sites, 26, in HIVSF2
gp120. The matrix-assisted laser desorption/ionization
(MALDI) spectrum of gp120 shows that the protein is
very heterogeneous with a molecular mass ranging
from 90,000–110,000 Da [7]. Based on the sequence, this
indicates that close to half of its mass is due to carbo-
hydrate residues. The differences include the number of
glycosylated sites and the types of glycans present.
Individual glycosylation sites may be occupied by
structurally different glycans, which give them the
ability to cover substantial parts of the peptide surface
of the viral glycoprotein [8]. The structure of gp120
reveals that many of the N-linked glycans could cover
regions of gp120 that would otherwise be exposed to
potentially neutralizing antibodies [9]. Also, the system
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glycosylation pattern, e.g., the glycosylation pattern
when gp120 is expressed in Chinese hamster ovarian
(CHO) cells will differ significantly from that expressed
in baculovirus [10].
There have been several reports on the determina-
tion of glycosylation sites and of the types of glycans
found on gp120. One research group found that the
gp120 glycans are primarily high mannose, hybrid, and
complex varieties, and more than 100 different glycans
could be identified [11, 12]. The major types of glycans
that can be found in a glycopeptide are shown in the
structures below. High mannose glycans consist pri-
marily of mannose (Man) with a maximum number of
nine mannoses possible unless not fully processed
(Structure 1), whereas the complex glycans are primar-
ily composed of N-acetylglucosamine (GlcNAc) and
galactose (Gal) with sialic acid (SA) (Structure 2). In the
complex glycans, both the number of N-acetylglu-
cosamine galactose (GlcNAc-Gal) units as well as the
number of sialic acids (SA) can vary. A fucose (Fuc)
may be added to the first GlcNAc in the core of the
complex glycans. The hybrid glycans are composed of
mannose, GlcNAc-Gal, and SA (Structure 3).
We have previously identified the major types of
glycans found on 25 of 26 consensus glycosylation sites
in HIV-ISF2 rgp120 expressed in CHO cells using nano-
electrospray and MALDI [13]. Using a molecular model
of intact glycosylated gp120 based on the crystal struc-
ture of a truncated highly deglycosylated construct [10],
high mannose glycans appear to cluster together on the
surface, as do complex glycans [13]. Consistent with
this model, it has been noted that mannose-binding
lectin (MBL) interacts with gp120 by binding to HIV-1
via high mannose or hybrid carbohydrates on gp120
Structures[14, 15]. MBL is a serum protein that binds to carbohy-drates on microorganisms and plays a role in the
clearance and destruction of these microorganisms [14,
16]. It has also been reported that high mannose glycans
of gp120 contribute largely to the MBL-HIV interaction
rather than host cell-derived glycoproteins [17].
There have been suggestions that modifications to
these glycans, such as the sialylation of the complex
glycans, could affect their potential biological activity
by possibly reducing the infectivity of human and
nonhuman primate lentivirus [18]. Sialic acids are a
family of naturally occurring derivatives of neuraminic
acid that play a role in biological and immunological
events. Sialylation usually occurs on glycoproteins em-
bedded in the plasma membrane, where the sialic acids
stabilize the plasma membranes by their negative
charge [19]. Removal of the fucose associated with
sialylated glycans has been shown to shift the protein
conformation, possibly exposing epitopes that were
located in the interior of gp120 [20]. Others have shown
that the removal of some sialic acids from rgp120
enhanced MBL binding [15]. It has also been shown in
a simian immunodeficiency virus (SIV) monkey model
that SIV-mutants lacking N-linked glycosylation are
more immunogenic compared to the wild type. This
report suggests that carbohydrates may be responsible
for masking immunodominant epitopes on external
glycoproteins and, thus, protect the virus against neu-
tralizing antibodies [21].
In our previous work, we were able to detect complex
and high mannose glycans at 25 of the 26 consensus sites
of HIV-ISF2 rgp120 [13], however, we could not detect the
presence of sialic acid residues on the complex glycopep-
tides using nanospray/MS or MALDI/MS, presumably
due to suppression effects associated with these two
ionization techniques. Harvey and co-workers used
MALDI/MS and normal-phase HPLC to investigate oli-
gosaccharides released from gel-separated proteins by
in-gel deglycosylation [22]. Thismethodwas used because
previous methods required the sialic acids of the glyco-
peptides or oligosaccharides be removed in order for the
glycans to be identified [9, 23]. Although various
MALDI/MS methods have been used to determine the
structure of sialylated glycans, successful applications of
thesemethods to the characterization of complexmixtures
of sialylated glycopeptides have not been reported. Gib-
son and co-workers [24] characterized sialylated complex
glycans using negative ion MALDI-TOF/MS, but, in our
initial study, we were unsuccessful in the characterization
of sialylated complex glycopeptides with this approach. If
the sensitivity of the sialylated glycopeptides was reduced
due to suppression by other components in the complex
proteolytic digests, we hypothesized that the nHPLC/
ESI/MS approach should reduce the complexity of the
mixture presented to the MS at any given time during the
analysis and, thus, reduce these suppression effects. We,
therefore, have analyzed the proteolytic digest of gp120
using nHPLC/ESI/MS as a means of characterizing the
sialylation of the complex glycopeptides from gp120.
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gp120 Sample Preparation
The HIV-ISF2 env gp120 (100 g) (Austral Biologicals,
San Ramon, CA), expressed in Chinese hamster ovary
(CHO) cells, was diluted in 152 L of 0.36 M Tris-HCl
buffer (pH 8.6), containing 8 M urea, 3 mM ethylenedi-
aminetetraacetic acid (EDTA), and 10 mM dithiothreitol
(DTT) and incubated under nitrogen for 4 h to reduce
disulfide bonds. Carboxymethylation was performed
by adding iodoacetic acid (Sigma, St. Louis, MO) to a
final concentration of 25 mM and incubating in the dark
for 45 min. The reaction was quenched by adding DTT
to a final concentration of 40 mM. The carboxymethyl-
ated gp120 was purified by HPLC on an Aglient model
1100 HPLC system (Palo Alto, CA) using a 25 cm  4.6
mm i.d. Vydac 214TP54 C4 column (Hesperia, CA).
Elution from the column was achieved using Solvents A
[water/0.1% trifluoroacetic acid (TFA)] and B (acetoni-
trile/0.1% TFA) with a linear gradient from 20% B to
60% B over 50 min, followed by a ramp from 60% B to
90% B over 10 min at a flow rate of 1 mL/min with
fractions collected at 1.5 min intervals. Collected frac-
tions were lyophilized, reconstituted in 20 L of 1:1
acetonitrile:0.1% formic acid, and analyzed for the pres-
ence of gp120 by MALDI/MS (as described below).
Those fractions containing gp120 were pooled into one
fraction and lyophilized to dryness. The lyophilized
gp120 was then reconstituted in 100 L of 50 mM
ammonium bicarbonate buffer (pH 7.95) and reana-
lyzed by MALDI/MS to confirm the presence of the
gp120.
Tryptic Digestion of gp120
The 100 L sample of gp120 was digested with 5 L of
1 g/L sequencing grade modified trypsin reconsti-
tuted in the supplied buffer of 50 mM acetic acid
(Promega, Madison, WI) at a ratio of 20:1 gp120: trypsin
(wt:wt). The tryptic digest was then analyzed by
MALDI/MS to ensure complete digestion.
MALDI-TOF/MS
The MALDI/MS used was an Applied Biosystems
Voyager-SUPER DE STR (Framingham, MA). MALDI/MS
analyses of the lyopholized gp120 fractions were per-
formed in the positive linear mode using an accelerat-
ing voltage of 25 kV, a grid voltage of 93%, and a delay
time of 400 ns. MALDI/MS analysis of the tryptic digest
was performed using an accelerating voltage of 20 kV, a
grid voltage of 95%, and a delay time of 400 ns in the
positive linear mode. Analysis of the tryptic digest in
the negative ion linear mode was performed using an
accelerating voltage of 25 kV, a grid voltage of 95%,
and a delay time of 150 ns. All analyses in the positive
ion mode were performed using a saturated solution of
-cyano-4-hydroxycinnamic acid in 45:45:10 water:eth-
anol:formic acid (vol:vol:vol) as the matrix. The analy-ses in the negative ion mode were performed using a
100 mM solution of 2,5-dihydroxybenzoic acid in 50%
acetonitrile as the matrix. External calibration was per-
formed using the Applied Biosystems (Framingham,
MA) calibration mixes.
nHPLC/ESI/MS
For the nHPLC/ESI/MS analyses, HPLC separations
were performed using an Agilent 1100 Series Capillary
LC. For LC separations acquired by positive ion ESI/
MS, a 15 cm  75 m i.d. PepMap C18 column (LC
Packings, San Francisco, CA) with a flow rate of 400
nL/min was used. An 8 L aliquot of the tryptic digest
was injected. The solvents used with this column were
the following: A, water/0.1% formic acid; and B, aceto-
nitrile/0.1% formic acid. A gradient of 8% B to 40% B
over 50 min, followed by a ramp from 40% B to 90% B
over 10 min was used to elute the tryptic peptides. For
LC separations acquired by negative ion ESI/MS, a 10
cm x 300 m i.d. ZORBAX 300Extend-C18 column
(Agilent Technologies) with a flow rate of 1.0 L/min
was used. The solvents used with this column were the
following: A, water/1.0% NH4OH; and B, acetonitrile/
1.0% NH4OH. The injection amount and gradient used
were the same as in the positive ion ESI/MS analyses.
The ESI spectra were obtained using either the
Q-TOF1 mass spectrometer (Micromass, Altrincham,
UK) or the Q-TOF Ultima Global mass spectrometer
(Waters/Micromass, Milford, MA), both of which are
equipped with a nanoflow z-spray source. The Q-TOF1
mass spectrometer was operated at a FWHM resolution
of 7500. The observed mass accuracy of high abundance
glycosylated peaks was approximately 0.008%, while
that of peaks of low abundance was lower,  0.07%.
Spectra were acquired in the positive ion mode over the
mass range of m/z 300–2500 with the source tempera-
ture at 80 °C, a capillary voltage of 3.00 kV, a cone
voltage of 30 V, a collision energy of 4.0 eV, and a scan
time of 1.9 s. The collision gas was argon at a gauge
pressure of 20 psi. The Q-TOF Ultima Global mass
spectrometer was operated at a FWHM resolution of
10,000 in V mode and a mass accuracy of 0.02%. The
spectra were acquired in the positive ion mode over the
mass range of m/z 300–2500 with the source tempera-
ture at 80 °C, a capillary voltage of 3.05 kV, a cone
voltage of 45 V, a collision energy of 10.0 eV, and a scan
time of 1.0 seconds. The collision gas was argon at a
gauge pressure of 25 psi. MS/MS analyses were per-
formed on the Q-TOF Ultima Global with all parame-
ters the same as in MS mode, except the collision energy
was 30.0 eV and the scan time was 1.9 s. The negative
ion ESI/MS spectra were acquired over the mass range
of m/z 100–3000 with the source temperature at 80 °C, a
capillary voltage of 3.0 kV, a cone voltage of 100 V,
a collision energy of 10.0 eV, and a scan time of 1.9 s.
The collision gas was argon at a pressure of 25 psi.
Peaks with a signal:noise greater than five were consid-
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substrate tetradecapeptide (Sigma).
Results and Discussion
HIV-ISF2 gp120 contains glycans primarily of high man-
nose, hybrid, and complex varieties (see Structures 1, 2,
and 3). A MALDI/MS spectrum of the carboxymethy-
lated gp120 tryptic digest is shown in Figure 1. Only
one tryptic peptide, m/z 4386, which corresponds in
mass to a potentially sialylated complex tryptic glyco-
peptide, T4, was observed. This peptide contains the
consensus glycosylation site N57. Bozue et al. have
previously shown that under negative ion MALDI/MS
conditions using a 100 mM solution of 2,5-dihydroxy-
benzoic acid as a matrix, sialylated complex oligosac-
charides could be readily detected [24]. When this
method was used to analyze the gp120 tryptic digest,
however, sialylated glycopeptides were not detected
(results not shown). This may be due to suppression of
the sialylated glycopeptides in the complex gp120 di-
gest mixture.
The HIV-ISF2 gp120 tryptic digest was then analyzed
by nHPLC/ESI/MS in both the positive and negative
ion mode in an effort to identify and characterize the
sialylated complex glycopeptides. The extent of sialyla-
tion on complex glycopeptides was determined by first
calculating the mass of the peptide with the glycan core
with or without fucose. The masses of the GlcNAc-Gal
and SA units were then added sequentially based on the
previous glycosylation characterization [13] with the
possible addition of one SA per GlcNAc-Gal. The
nHPLC/ESI/MS data were then searched for these
corresponding masses. Table 1 shows the amino acid on
which a sialylated glycan was found, the tryptic pep-
tides containing the sites, and the masses of the glyco-
peptides. The table also includes the number of Glc-
NAc-Gal residues observed and the extent of sialylation
(SA residues) along with the relative abundance of
each. The relative abundances of the summed intensi-
ties of all isotope peaks over the elution window of
Figure 1. MALDI/MS spectrum of the tryptic digest of gp120
with peptides labeled. The dagger indicates a sialylated peptide.
The asterisk indicates a peak that could not be identified.specific glycosylated peptides were normalized with
the most abundant ion being 100%. It should be noted
that the relative abundances correspond to the abun-
dance ratios observed in the raw data, and that differ-
ences in sensitivity and ionization efficiency were not
considered. Figure 2 shows the positive ion nHPLC/
ESI/MS spectra of two tryptic peptides in which the
extent of complex glycans had been previously identi-
fied [13] but not the degree of sialylation because the
sample had been desialylated. The summed spectrum
in Figure 2a shows the glycan composition for N170,
which is contained in tryptic peptide T15. This glycan is
fucosylated and contains 2–4 GlcNAc-Gal units as well
as 1–3 sialic acids. We had previously observed 2–5
GlcNAc-Gal units at this site [13], however, in our
current study, an ion corresponding to the fifth Glc-
NAc-Gal was not detected in any charge state. This lack
of detection may be consistent with the fact that the
relative abundance was also very low in our previous
characterization by nanospray or that the more exten-
sively sialylated glycopeptides have significantly re-
duced sensitivities compared to less highly sialylated
glycopeptides in the nHPLC/ESI/MS analyses. The
summed spectrum containing the fucosylated peptide
T40 (N428(P)/431) is shown in Figure 2b and these data
indicate the presence of 1–3 GlcNAc-Gals with 1–3 sialic
acids. Previously, we could not determine the extent of
sialylation for this site, but were able to characterize the
presence of 1–7 GlcNAc-Gal units [13]. Glycopeptides
which were observed previously with higher GlcNAc-
Gal and SA units [13] were not observed here, presum-
ably due to their high masses and charge.
Previously, we reported that the glycan group at
residue N274 was complex, but we were unable to
characterize the heterogeneity at this position [13]. In
addition, the carbohydrate chain at residue N415, could
not be determined. Using the nHPLC/ESI/MS ap-
proach, however, we were able to determine the glycan
at this residue to be complex. Figure 3 shows the
positive ion nHPLC/ESI/MS spectra of these two pre-
viously uncharacterized complex glycans. From the
summed mass spectrum containing peptide T22 (Figure
3a), which contains the glycosylation site at residue
N274, we could determine that this glycopeptide is
fucosylated and contains 1–4 GlcNAc-Gal units and 1–2
sialic acids. The summed spectrum containing the gly-
copeptide T39 (Figure 3b), with a consensus glycosyla-
tion site at amino acid N415, shows that the glycan
structure for this peptide has 1–3 GlcNAc-Gal units and
1–2 sialic acids.
In an attempt to gain structural information about
the glycopeptides as well as sequence information,
nHPLC/ESI/MS/MS analyses were performed. Figure
4 shows a representative positive ion MS/MS spectrum
obtained for m/z 1419.1 corresponding in mass to the
fucosylated tryptic peptide T40, which contains glyco-
sylation sites N428(P)/431, and has 2 GlcNAc-Gal units
and 1 SA unit. As can be seen from this MS/MS
spectrum, fragmentation of the sialylated complex gly-
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Site Tryptic peptide
Glycopeptide mass
c(GlcNAc-Gal)x(SA)y 
Fuc
Relative
abundance (%)aTheo. bObs.
N99 T6 3110.3 3110.4 (GlcNAc-Gal)1  Fuc 100
d(K)LTPLBVTLNBTDLGK(A) 3401.4 3401.8 (GlcNAc-Gal)1(SA)1  Fuc 68
3475.5 3475.2 (GlcNAc-Gal)2  Fuc 84
3766.6 3767.5 (GlcNAc-Gal)2(SA)1  Fuc 53
4057.7 4058.2 (GlcNAc-Gal)2(SA)2  Fuc 53
3840.6 3841.5 (GlcNAc-Gal)3  Fuc 74
N110 T7 2745.1 2746.1 (GlcNAc-Gal)2  Fuc 79
(K)ATNTNSSNWK(E) 3036.2 3036.3 (GlcNAc-Gal)2(SA)1  Fuc 42
3327.3 3327.1 (GlcNAc-Gal)2(SA)2  Fuc 53
3110.3 3110.5 (GlcNAc-Gal)3  Fuc 100
3401.4 3400.1 (GlcNAc-Gal)3(SA)1  Fuc 84
3475.5 3475.2 (GlcNAc-Gal)4  Fuc 65
3766.6 3767.5 (GlcNAc-Gal)4(SA)1  Fuc 53
4057.7 4058.7 (GlcNAc-Gal)4(SA)2  Fuc 53
N170 T15 2582.0 2581.2 (GlcNAc-Gal)2  Fuc 48
(R)LIHBNR(S) 2873.1 2872.8 (GlcNAc-Gal)2(SA)1  Fuc 98
3164.2 3164.5 (GlcNAc-Gal)2(SA)2  Fuc 100
2947.2 2945.7 (GlcNAc-Gal)3  Fuc 35
3238.3 3237.2 (GlcNAc-Gal)3(SA)1  Fuc 39
3529.4 3528.9 (GlcNAc-Gal)3(SA)2  Fuc 55
3820.5 3819.9 (GlcNAc-Gal)3(SA)3  Fuc 29
3312.3 3310.2 (GlcNAc-Gal)4  Fuc 19
3603.4 3602.8 (GlcNAc-Gal)4(SA)1  Fuc 29
3894.5 3893.6 (GlcNAc-Gal)4(SA)2  Fuc 35
4185.6 4186.1 (GlcNAc-Gal)4(SA)3  Fuc 24
N249 T21 2779.1 2777.9 (GlcNAc-Gal)2  Fuc 68
(R)SDNFTNNAK(T) 3070.2 3069.8 (GlcNAc-Gal)2(SA)1  Fuc 100
3361.3 3362.8 (GlcNAc-Gal)2(SA)2  Fuc 45
3144.2 3142.7 (GlcNAc-Gal)3  Fuc 50
3435.3 3434.2 (GlcNAc-Gal)3(SA)1  Fuc 64
2998.2 2997.5 (GlcNAc-Gal)3  Fuc 73
3289.3 3288.2 (GlcNAc-Gal)3(SA)1  Fuc 50
3580.4 3579.7 (GlcNAc-Gal)3(SA)2  Fuc 64
3871.5 3872.3 (GlcNAc-Gal)3(SA)3  Fuc 55
N274 T22 3932.3 3930.9 (GlcNAc-Gal)1  Fuc 12
(K)TIIVQLNESVAINBTRPNNNTR(K) 4223.4 4222.2 (GlcNAc-Gal)1(SA)1  Fuc 16
4297.5 4296.7 (GlcNAc-Gal)2  Fuc 88
4588.6 4587.5 (GlcNAc-Gal)2(SA)1  Fuc 78
4662.6 4661.6 (GlcNAc-Gal)3  Fuc 39
4953.7 4954.1 (GlcNAc-Gal)3(SA)1  Fuc 37
5244.8 5243.8 (GlcNAc-Gal)3(SA)2  Fuc 27
5027.7 5028.8 (GlcNAc-Gal)4  Fuc 22
5318.8 5319.9 (GlcNAc-Gal)4(SA)1  Fuc 100
5609.9 5609.5 (GlcNAc-Gal)4(SA)2  Fuc 63
N415 T39 3925.5 3926.1 (GlcNAc-Gal)1  Fuc 14
(K)AMYAPPIGGQISBSSNITGLLLTR(D) 4216.5 4216.1 (GlcNAc-Gal)1(SA)1  Fuc 13
4290.6 4291.1 (GlcNAc-Gal)2  Fuc 100
4581.7 4582.4 (GlcNAc-Gal)2(SA)1  Fuc 69
4655.7 4656.2 (GlcNAc-Gal)3  Fuc 20
4946.8 4947.2 (GlcNAc-Gal)3(SA)1  Fuc 42
5237.9 5237.6 (GlcNAc-Gal)3(SA)2  Fuc 31
N428e(P)/N431 T40 3598.5 3597.9 (GlcNAc-Gal)1  Fuc 4
(R)DGGTNVTNDTEVFRPGGGDMR(D) 3889.6 3888.6 (GlcNAc-Gal)1(SA)1  Fuc 6
3963.6 3963.5 (GlcNAc-Gal)2  Fuc 5
4254.7 4254.3 (GlcNAc-Gal)2(SA)1  Fuc 100
4545.8 4544.9 (GlcNAc-Gal)2(SA)2  Fuc 90
4328.8 4328.2 (GlcNAc-Gal)3  Fuc 2
4619.9 4618.8 (GlcNAc-Gal)3(SA)1  Fuc 7
4910.9 4911.5 (GlcNAc-Gal)3(SA)2  Fuc 16
5202.0 5201.1 (GlcNAc-Gal)3(SA)3  Fuc 9
aTheo.  theoretical.
bObs.  observed.
cGlcNAc-Gal N-acetylglucosamine and galactose, x the number of GlcNAc-Gal units, SA sialic acid, y the number of SA units, and Fuc fucose.
dB  carboxymethylcysteine.
eP  partially glycosylated.
amino acid sequence B  carboxymethylcysteine.
1550 CUTALO ET AL. J Am Soc Mass Spectrom 2004, 15, 1545–1555Figure 3. Positive ion nHPLC/ESI/MS spectra summed over the chromatographic retention
window in which complex glycopeptides (a) N274 and (b) N415 eluted. For figure clarity, the peaks
corresponding to other tryptic peptides/glycopeptides are not labeled. Filled square  GlcNAc-Gal,
filled diamond  sialic acid, and filled triangle  fucose; the number before each symbol indicates
how many of each are present. The superscripted number is the charge state. In the amino acidFigure 2. Positive ion nHPLC/ESI/MS spectra summed over the chromatographic retention
window in which complex glycopeptides (a) N170 and (b) N428(P)/431 eluted. The inset in panel (a)
is for the ion corresponding to [(4)‘]3. The inset in panel (b) is for the ion corresponding to [(3)
‘]3. Both insets are of spectra summed over the elution window of that component. For figure
clarity, the peaks corresponding to other tryptic peptides/glycopeptides are not labeled. Filled square
 GlcNAc-Gal, filled diamond  sialic acid, and filled triangle  fucose; the number before each
symbol indicates how many of each are present. The superscripted number is the charge state. In thesequence B  carboxymethylcysteine.
e.
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(or any other MS/MS spectrum of a complex glycopep-
tide), however, could be assigned to the peptide back-
bone. Thus the spectrum does not provide direct infor-
mation about the peptide sequence.
Based on the low relative abundance of ions for the
sialylated peptides, suppression effects in the positive
ion mode may be decreasing the sensitivity of these
peptides. Increasing numbers of sialic acid residues on
peptides may lead to an overall negative net charge,
and, thus, result in a lack of observation of these
peptides. Therefore, negative ion nHPLC/ESI/MS anal-
yses were performed in order to obtain better coverage
of the complex glycan sites. Under these conditions,
however, no complex glycans could be identified (data
not shown).
Because one of the glycosylation sites was found to
contain high mannose glycans in this study, but was
previously characterized to contain complex glycans
[13], the high mannose glycosylation sites were further
investigated using the nHPLC/ESI/MS approach. Fig-
ure 5 shows the positive ion nHPLC/ESI/MS spectra of
two glycopeptides in which the glycan structure was
previously determined to be high mannose, but the
number of mannoses had not been determined and two
glycosylated peptides found in partial peptides, which
arose from anomalous cleavages. The mass spectrum of
tryptic peptide T32 (Figure 5, labeled as ion series a)
shows that the glycan at N328 has 3–8 mannoses
present, where previously the number of mannoses
could not be determined. The mass spectrum of the
Figure 4. Positive ion nHPLC/ESI/MS/MS sp
containing complex glycans at sites N428(P)/431
state spectrum using MaxEnt. GlcNAc  N-ace
and galactose; SA  sialic acid; Man  Mannospartial peptide T14= (Figure 5, labeled as ion series b),residues 154–161 (unconfirmed by MS/MS due to the
lack of peptide sequence ions), which contains glyco-
sylation sites N154/160=, shows 4–8 mannoses present.
The site where this glycan chain in the peptide sequence
was located could not be distinguished between the
N154 and N160 sites. However, based on theoretical
calculations, it is likely that only one site is occupied
and not both because the observed mass is less than the
theoretical mass of the glycopeptide with the core
glycosylation at both sites. The full-length T14 peptide
(amino acids 146 to 165) was also observed in these
nHPLC/ESI/MS analyses as having 0–6 mannoses
present. Using MALDI/MS, this same peptide was
previously characterized by our group to only contain
complex glycans [13]. In Figure 5, the ions labeled as
series c show the anomalously cleaved partial peptide
T34= (which contains residues 357–363 and the consen-
sus glycosylation site N358=) as having 3–8 mannoses
present. The corresponding full-length peptide (which
contains the consensus site N358 as well as site N364)
was characterized previously as having 11–18 manno-
ses [13]. In Figure 5, the ions labeled as series d show
the mass spectrum of peptide T35 with site N370 shows
4–8 mannoses in the glycan chain, which had not been
determined previously.
Table 2 shows the summary of glycosylation sites
where high mannose (HM) glycans were found in these
experiments. The corresponding tryptic peptides con-
taining these glycosylation sites, the masses of the
glycopeptides, the number of mannoses observed, as
well as their corresponding relative abundances are also
m of the peptide [(M  3H)3 ion of m/z 1419.1]
transformation of all ions into the single charge
cosamine; GlcNAc-Gal  N-acetylglucosamineectru
after
tylglushown. The relative abundances were determined in the
erscr
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numbers of mannoses cannot be seen that were present
in our previous work for some of the peptides. One
possibility is that the gp120 being used is from a
different lot. The observation of an abundant nine
mannose glycan at higher m/z (T6, N99) argues against
a dramatic decrease in sensitivity for nine mannose
glycosylated peptides, and the observation of relatively
abundant eight mannose glycopeptides make suppres-
sion effects relatively unlikely.
During protein high mannose glycosylation, a pre-
cursor oligosaccharide composed of N-acetylglu-
cosamine (GlcNAc), mannose (Man), and glucose (Glc)
is transferred to proteins in the endoplasmic reticulum
(ER). The diversity of these N-linked oligosaccharide
structures on mature glycoproteins results from exten-
sive modification of the precursor structure. While still
in the ER, the glucose residues are quickly removed
from the oligosaccharides of most glycoproteins. This
process known as oligosaccharide “trimming” contin-
ues in the Golgi apparatus, and thus the glucose is not
seen on the glycoprotein [25]. Figure 6 shows the
negative ion nHPLC/ESI/MS spectrum of a high man-
nose glycopeptide, T6, which was not fully processed.
These data show that high mannose glycosylation of
this peptide occurs (most likely at residue N99 with 9
mannoses present). The ions of m/z 1406.7 and 1460.8
correspond to the tryptic peptide with nine mannoses
plus one and two Glcs, respectively, indicating that
Figure 5. Positive ion nHPLC/ESI/MS spectra
cleavage partial peptides containing high manno
and (d) N370. The prime symbol indicates a partia
high mannose consensus site N304 are labeled wit
that were not identified are labeled with a dagger
number present, where Man  mannose. The supcomplete “trimming” did not occur.Conclusions
nHPLC/ESI/MS was used to characterize the glycosyl-
ation and extent of sialylation of HIV-ISF2 gp120. Spe-
cifically, we have shown that both sialylated complex
glycans and high mannose glycans are present. We
were able to determine the sialylation profile of eight of
the fifteen sites that have been shown to contain com-
plex glycans. The glycosylation sites for complex gly-
cans which could be determined are N99, N110, N170,
N249, N274, N415, and N428(P)/431. The other consen-
sus complex sites that could not be characterized are
N57, N124/128, N154/160, N235, and N378. A number
of factors may be involved in our inability to profile the
extent of sialylation of the remaining complex glyco-
peptides. A combination of all these factors which may
have contributed include high mass tryptic peptides
(some of which have m/z greater than 5000), multiple
glycosylation sites within one peptide, the large num-
ber of negatively charged groups present, and possible
incomplete digestion.
Since a previously determined complex glycan site
was observed to be high mannose as well in these
analyses, we investigated the high mannose glycans
and were able to determine the number of mannoses
present on thirteen of the nineteen sites containing high
mannose glycans. These consensus sites are N99, N154/
160, N170, N203, N214/235, N304, N328, N334, N358,
N370, and N378. Glycosylation sites N154/160 and
eptide with high mannoses and the anomalous
nsensus sites (a) N328, (b) N154/160=, (c) N358=,
tide. For figure clarity, the peaks corresponding to
asterisk. Other tryptic peptides are labeled. Peaks
bol. The mannoses are labeled depending on the
ipted number is the charge state.of a p
se co
l pep
h an
symN358 were observed in two peptides with anomalous
1553J Am Soc Mass Spectrom 2004, 15, 1545–1555 LC/MS OF gp120 GLYCOPEPTIDESTable 2. Heterogeneity and relative abundances determined for high mannose glycans using nHPLC/ESI/MS
Site Tryptic peptide
Glycopeptide mass
cMan
Relative
abundance (%)aTheo. bObs.
N99 T6 3570.5 3569.5 6 Man 36
d(K)LTPLBVTLNBTDLGK(A) 3732.5 3731.6 7 Man 33
3894.6 3893.5 8 Man 64
4056.6 4055.5 9 Man 37
4218.7 4217.8 9 Man  Glc 91
4380.7 4379.9 9 Man  2Glc 100
eN154/160= T14= 2411.4 2410.4 4 Man 55
(D)NASTTTNY(T) 2573.4 2572.2 5 Man 93
2735.5 2734.1 6 Man 79
2897.5 2896.8 7 Man 100
3059.6 3058.7 8 Man 34
N154/160 T14 3163.8 3164.9 Peptide  Core 4
(R)NLDVVPIDNASTTTNYTNYR(L) 3325.8 3326.0 1 Man 33
3487.9 3488.1 2 Man 54
3649.9 3650.1 3 Man 100
3812.0 3812.1 4 Man 32
3974.0 3974.1 5 Man 47
4136.1 4136.3 6 Man 58
N170 T15 2839.1 2840.5 7 Man 45
(R)LIHBNR(S) 3001.1 3002.4 8 Man 80
3163.2 3164.2 9 Man 100
N203 T18 2075.7 2074.8 4 Man 28
(K)BNNK(T) 2237.8 2236.6 5 Man 75
2399.8 2398.4 6 Man 70
2561.9 2561.2 7 Man 100
2723.9 2723.0 8 Man 83
2886.0 2885.7 9 Man 95
N214/235 T20 4943.9 4944.4 Peptide  Core 22
(K)GPBTNVSTVQBTHGIRPIVSTQLLL 5106.0 5107.2 1 Man 24
NGSLAEEEVVIR(S) 5268.0 5269.2 2 Man 28
5430.1 5431.1 3 Man 28
5592.2 5593.1 4 Man 50
5754.2 5755.3 5 Man 75
5916.3 5917.1 6 Man 100
N304 T28 2397.9 2398.5 4 Man 70
(K)AHBNISR(A) 2559.9 2559.3 5 Man 100
2722.0 2722.1 6 Man 85
2884.1 2883.8 7 Man 95
3046.1 3044.5 8 Man 25
N328 T32 2213.9 2212.7 3 Man 40
(R)EQFGNNK(T) 2375.9 2374.5 4 Man 46
2537.9 2536.3 5 Man 67
2700.0 2699.1 6 Man 65
2862.0 2860.9 7 Man 100
3024.1 3022.6 8 Man 38
N334 T33 3551.1 3550.2 1 Man 25
(K)TIVFNQSSGGDPEIVMHSFNBR(G) 3713.2 3712.4 2 Man 28
3875.2 3874.5 3 Man 56
4037.3 4036.5 4 Man 55
4199.4 4198.4 5 Man 100
4361.4 4360.4 6 Man 66
N358= T34= 2262.5 2263.5 3 Man 45
(Y)BNTTQLF(N) 2424.5 2425.4 4 Man 53
2586.6 2587.2 5 Man 88
2748.6 2748.9 6 Man 69
2910.7 2910.7 7 Man 100
3072.7 3072.7 8 Man 39
N370 T35 2439.0 2439.3 4 Man 74
(R)LNHTEGTK(G) 2601.0 2601.6 5 Man 96
2763.1 2763.8 6 Man 87
2925.2 2925.7 7 Man 100
3087.2 3087.6 8 Man 80
N378 T36 2699.1 2698.1 4 Man 65
(K)GNDTIILPBR(I) 2861.2 2861.8 5 Man 100
3023.2 3021.6 6 Man 38
3185.3 3184.2 7 Man 17
aTheo.  theorectical.
bObs.  observed.
cMan  mannose.
dB  carboxymethylcysteine.
e=  Partial peptide.
1554 CUTALO ET AL. J Am Soc Mass Spectrom 2004, 15, 1545–1555cleavage sites and had not been previously observed or
characterized. Since most glycans on mature glycopro-
teins are first processed, it is interesting that glycosyla-
tion site N99 was observed as still possessing one and
two glucose molecules, thus, indicating this glycan was
not fully processed.
Due to the complexity of the gp120 tryptic digest
mixture, it is possible that suppression or low protona-
tion efficiency of the negatively ionized sialic acid
residues still occurs. This appears to be leading to the
suppression of the higher mass glycopeptides by the
presence of the abundant lower mass peptides. There-
fore, the sensitivity of the sialylated peptides is de-
creased. The maximum number of SA residues ob-
served was three. An increase in the number of SA
residues on a peptide may lead to a net negative charge
of the peptide, thereby, resulting in these peptides
being not observed in the positive ion MS spectra. No
sialylated peptides, however were identified in the
negative ion nHPLC/ESI/MS analyses of the digest.
Future work will focus on alternative proteolysis steps
and/or affinity purification of the glycopeptides. As
demonstrated here, nHPLC/ESI/MS can be used as a
method to characterize the type of glycan present in a
glycopeptide, as well as to determine the extent of
sialylation (within the experimental limits). These anal-
yses in combination with previous efforts [13] have now
allowed the characterization of all 26 consensus glyco-
sylation sites on HIV-ISF2 gp120.
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